iBio, Inc. Common Stock (IBIO) - Total Assets
Based on the latest financial reports, iBio, Inc. Common Stock (IBIO) holds total assets worth $64.16 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IBIO stock price and chart for real-time trading data and today's change.
iBio, Inc. Common Stock - Total Assets Trend (2007–2025)
This chart illustrates how iBio, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see IBIO operating cash flow for how efficiently the company converts equity into cash flow.
iBio, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (June 2025)
iBio, Inc. Common Stock's total assets of $64.16 Million consist of 41.9% current assets and 58.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.0% |
| Accounts Receivable | $105.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $6.85 Million | 29.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how iBio, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore iBio, Inc. Common Stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: iBio, Inc. Common Stock's current assets represent 41.9% of total assets in 2025, an increase from 4.7% in 2007.
- Cash Position: Cash and equivalents constituted 37.0% of total assets in 2025, up from 0.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, a decrease from 88.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 29.5% of total assets.
iBio, Inc. Common Stock Competitors by Total Assets
Key competitors of iBio, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
iBio, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.39 | 3.37 | 18.17 |
| Quick Ratio | 8.39 | 3.37 | 18.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $44.72 Million | $8.24 Million | $104.78 Million |
iBio, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between iBio, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.42 |
| Latest Market Cap to Assets Ratio | 1.08 |
| Asset Growth Rate (YoY) | -19.3% |
| Total Assets | $23.18 Million |
| Market Capitalization | $24.96 Million USD |
Valuation Analysis
Above Book Valuation: The market values iBio, Inc. Common Stock's assets above their book value (1.08x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: iBio, Inc. Common Stock's assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for iBio, Inc. Common Stock (2007–2025)
The table below shows the annual total assets of iBio, Inc. Common Stock from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $23.18 Million | -19.31% |
| 2024-06-30 | $28.73 Million | -30.27% |
| 2023-06-30 | $41.21 Million | -58.55% |
| 2022-06-30 | $99.41 Million | -32.36% |
| 2021-06-30 | $146.97 Million | +56.04% |
| 2020-06-30 | $94.19 Million | +207.95% |
| 2019-06-30 | $30.59 Million | -29.01% |
| 2018-06-30 | $43.08 Million | +19.64% |
| 2017-06-30 | $36.01 Million | -30.21% |
| 2016-06-30 | $51.60 Million | +313.00% |
| 2015-06-30 | $12.49 Million | +92.39% |
| 2014-06-30 | $6.49 Million | -30.58% |
| 2013-06-30 | $9.35 Million | -4.20% |
| 2012-06-30 | $9.76 Million | +33.11% |
| 2011-06-30 | $7.34 Million | +48.79% |
| 2010-06-30 | $4.93 Million | 0.00% |
| 2009-06-30 | $4.93 Million | +38.91% |
| 2008-06-30 | $3.55 Million | -5.81% |
| 2007-06-30 | $3.77 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more